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Abstract
Background: Panic disorder (PD) and generalized anxiety disorder (GAD) are two of the most disabling and costly anxiety
disorders seen in primary care. However, treatment quality of these disorders in primary care generally falls beneath the
standard of international guidelines. Collaborative stepped care is recommended for improving treatment of anxiety disorders,
but cost-effectiveness of such an intervention has not yet been assessed in primary care. This article describes the aims and
design of a study that is currently underway. The aim of this study is to evaluate effects and costs of a collaborative stepped care
approach in the primary care setting for patients with PD and GAD compared with care as usual.
Methods/design: The study is a two armed, cluster randomized controlled trial. Care managers and their primary care
practices will be randomized to deliver either collaborative stepped care (CSC) or care as usual (CAU). In the CSC group a
general practitioner, care manager and psychiatrist work together in a collaborative care framework. Stepped care is provided
in three steps: 1) guided self-help, 2) cognitive behavioral therapy and 3) antidepressant medication. Primary care patients with
a DSM-IV diagnosis of PD and/or GAD will be included. 134 completers are needed to attain sufficient power to show a clinically
significant effect of 1/2 SD on the primary outcome measure, the Beck Anxiety Inventory (BAI). Data on anxiety symptoms,
mental and physical health, quality of life, health resource use and productivity will be collected at baseline and after three, six,
nine and twelve months.
Discussion: It is hypothesized that the collaborative stepped care intervention will be more cost-effective than care as usual.
The pragmatic design of this study will enable the researchers to evaluate what is possible in real clinical practice, rather than
under ideal circumstances. Many requirements for a high quality trial are being met. Results of this study will contribute to
treatment options for GAD and PD in the primary care setting. Results will become available in 2011.
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Anxiety disorders are a great burden for patients, the gen-
eral health system and society as a whole. Patients having
an anxiety disorder suffer from considerable disability
and reduced quality of life [1]. In addition, anxiety disor-
ders are associated with significant costs due to the use of
health services and reduced productivity [2].
Of the anxiety disorders, panic disorder (PD) and general-
ized anxiety disorder (GAD) are the most disabling [3]
and costly [4-6] anxiety disorders that are frequently seen
in primary care. Research has indicated that four to seven
percent of primary care attendees suffer from one or both
of these anxiety disorders [7-10].
As the majority of these patients is only seen in primary
care [6,11], this may be a convenient setting to treat these
disorders. Treatment for PD and GAD can be highly effec-
tive [12,13]. In recent decades the evidence for the effec-
tiveness of treatments for anxiety disorders has been
reviewed and described in clinical guidelines for treat-
ment, where cognitive behavioral therapy as well as pre-
scription of antidepressants are considered as first choice
of treatment for PD and GAD [14-16]. However, these
guidelines are rarely adhered to in primary care. About
one third of patients with an anxiety disorder treated in
primary care receive appropriate treatment as defined by a
minimal accordance with existing guidelines [6,17,18].
One of the reasons for the low quality of treatment is poor
recognition of anxiety disorders. Even when compared to
depression, the recognition rate of anxiety disorders is
low, with about one third of anxiety disorder patients
labeled as such by their general practitioner (GP) [19-21].
Several factors are involved in this low recognition rate,
such as patients unwillingness or inability to discuss their
anxiety problems with their GP [11,22,23] and limited
knowledge of GPs about psychiatric disorders. Moreover,
GPs frequently work under time pressure and perceive
they have not enough time to enquire about emotional
problems. In conclusion, competing demands of the
patient, the GP and the primary care structure of acute epi-
sodic care make diagnosing mental health problems diffi-
cult [24].
Although ameliorating recognition of anxiety disorders is
necessary [25], it is not sufficient for improving primary
health care for these patients [26-28]. GPs often feel they
do not have the necessary capabilities to treat these prob-
lems [23,29]. Moreover, the primary care system does not
seem to be well organized for care for anxiety disorders
[25]. As anxiety disorders often have a chronic nature
[30], they make a poor fit with the acute disease model of
primary care [10]. Therefore, several researchers have pro-
posed to use a chronic care model to implement evidence
based care into practice. The most promising of these
strategies are based on Wagner's model of care for chronic
diseases [31]. This model was originally developed to
improve treatment for chronic diseases like diabetes. The
strategies following Wagner's model involve collaborative
disease management with a pivotal role for a "care man-
ager", who coordinates care, works according to an evi-
dence-based treatment protocol, monitors treatment
response and actively follows the patient. This care man-
ager usually is a non-physician professional, who works in
close collaboration with the GP. Care manager and GP are
further assisted by a specialist from secondary care. This
model was adopted for use with mental disorders, with a
nurse practitioner or a psychologist as care manager and a
psychiatrist functioning as consultant specialist [32,33].
This collaborative care model has been tested extensively
in the treatment of depression, showing robust positive
results [34,35]. A few studies in the United States have
investigated the effectiveness of collaborative care for anx-
iety disorders, especially PD [36-38] and GAD [37]. When
compared to other strategies for improving care for anxi-
ety disorders in ambulatory care, collaborative care seems
to be the most effective [39]. In two of the studies
described above a cost-effectiveness analysis was per-
formed. In both studies, collaborative care was more effec-
tive than care as usual. Results regarding cost effectiveness
were inconclusive, with collaborative care being either
more or less costly than care as usual [40,41]. Researchers
of these collaborative care trials [36] and international
guidelines [15] recommend a stepped care approach for
mental health care in primary care, with least invasive and
costly interventions preceding more invasive and expen-
sive forms of care. Such an approach may make collabora-
tive care interventions more cost-effective.
This article describes the aims and methods of a rand-
omized controlled trial to test the effectiveness of a collab-
orative stepped care intervention for PD and GAD in
primary care in the Netherlands. Such a study is warranted
for two reasons. First, there has been no study on the cost-
effectiveness of a collaborative care intervention for anxi-
ety disorders that includes a stepped care approach. Sec-
ond, published studies about collaborative care for
anxiety disorders all stem from the United States (US),
where the collaborative care model was originally devel-
oped. As there are significant differences across health care
systems in the US and in European countries [42], the
results of the collaborative care studies might not be gen-
eralized to other countries without consideration. To fill
this gap in research, we designed a collaborative stepped
care intervention for GAD and PD in the primary care set-
ting. The treatment algorithm is built up from three inter-
ventions that have separately been proven effective and
feasible in the primary care setting [29,43]. The interven-Page 2 of 12
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therapy, and antidepressant medication [43]. Other ele-
ments of collaborative care include a trained care manager
(a mental health practice nurse or psychologist) who
coordinates care and provides psychological treatment,
the availability of a consultant psychiatrist for advising GP
and care manager, telephone follow-up by the care man-
ager and monitoring of anxiety symptoms to evaluate
treatment progress and outcome. Effects and costs of the
interventions will be assessed and an economic evalua-
tion will be performed to estimate cost-effectiveness and
cost-utility of the intervention. All relevant costs to society
associated with the burden of anxiety disorders will be
taken into account. In accordance with the outcomes of
similar previous studies, it is hypothesized that the collab-
orative stepped care intervention will be at least more
effective and possibly less expensive than care as usual.
Methods/Design
Objectives
The primary aim of this randomized controlled trial
(RCT) is to evaluate the effectiveness of collaborative
stepped care (CSC) versus care as usual (CAU) in the treat-
ment of panic disorder (PD) and generalized anxiety dis-
order (GAD) in primary care, with severity of anxiety
symptoms as primary outcome measure. The secondary
aim is to evaluate cost-effectiveness (costs of the interven-
tion weighed against a reduction in anxiety symptoms)
and to estimate cost-utility (costs of the intervention
weighed against gained Quality Adjusted Life Years
(QALY's)).
Study design
The study design is a two-armed, cluster randomized, con-
trolled trial.
Time frame
This study was initiated in 2008 and will take three years.
Results are expected in 2011.
Recruitment of GPs, care managers and psychiatrists
The study is designed in cooperation with the Netherlands
Institute of Mental Health and Addiction (Trimbos Insti-
tute), the Department of General Practice and Psychiatry
of the VU University Medical Centre in Amsterdam and
the Department of Public Health and Primary Care of the
Leiden University Medical Centre. GPs in the Leiden
region that are located in the region of a large mental
health centre (Rivierduinen) will receive an invitation to
participate in the study, after which a researcher (AM) will
contact all practices by phone to recommend participa-
tion. Participating practices will be able to decide which
professional (e.g. a psychologist, a mental health practice
nurse or a social worker) will fulfill the role of care man-
ager. If the practice does not have such a professional
available, a mental health practice nurse working at the
regional mental health centre will be available to work in
the practice. Experienced psychiatrists working at the
regional mental health centre will perform as consultant
psychiatrists for the intervention practices.
Randomization
Cluster randomization will be applied at the level of the
care manager to minimize contamination of the effect
[44]. Randomization will be performed using sequences
obtained with an automated random sequence generation
algorithm following a blocking scheme of variable length
with allowance for restricted unbalance of at most three.
Stratification will be on region, with six regions in total,
which are based on working units of the regional mental
health centre. The allocation sequences will be generated
by an independent statistician (HA) in the manner
described above. The care managers will be randomized
and allocated to the intervention (CSC) or the control
group (CAU). PCPs and GPs will be allocated to either
CSC or CAU in accordance with the randomization status
of their care manager. After randomization, neither care
managers nor GPs will be blinded to group assignment.
Figure 1 presents a flowchart of the recruitment and rand-
omization procedure.
Patient inclusion and exclusion criteria
Patients with a primary diagnosis of PD with or without
agoraphobia and/or a primary diagnosis of GAD accord-
ing to the criteria of the DSM IV [45] will be included in
the study. Patients who are suicidal, suffer from dementia
Flowchart showing the recruitment and randomization of care m nagers and practicesigure 1
Flowchart showing the recruitment and randomiza-
tion of care managers and practices. GP: general practi-
tioner, PCP: primary care practice, CM: care manager.Page 3 of 12
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bipolar disorder, dependence on drugs or alcohol, or with
an unstable severe medical condition as diagnosed by
their GP or as assessed in a diagnostic interview will be
excluded. Patients with insufficient knowledge of the
Dutch language to fill out the questionnaires, patients
who are already receiving intensive psychological treat-
ment (>2 contacts per month with a psychologist or psy-
chiatrist) and patients who are under 18 years of age will
also be excluded from the study. For reasons of generali-
zation, no other exclusion criteria are used. Having
received treatment for anxiety problems in the past, using
medication (e.g. antidepressants or benzodiazepines) or a
diagnosis of co-morbid psychiatric and medical condi-
tions (except for those described above) will not be rea-
sons for exclusion.
Recruitment of patients
Recruitment of patients will take place in two phases: a
screening phase and a diagnostic phase. Patients will
either be referred by their GP or will receive an invitation
to participate based on a selection of the electronic medi-
cal record system of the GP. Patients are blinded for rand-
omization status until they have returned the baseline
questionnaire.
Screening phase
GPs are able to refer a patient by handing a patient an
information letter, an informed consent form and a short
screening instrument: the Patient Health Questionnaire
anxiety subscale (PHQ22) [46]. This measure has shown
good psychometric properties for screening for anxiety
disorders [46,47].
In cluster randomization, when dependent on referrals of
GPs, a known problem is the inclusion of patients in the
CAU group [48]. To diminish recruitment bias, referral by
GPs is complemented with selection on basis of screening
in this study. A number of patients will be selected from
the electronic medical records of the GPs according to the
following criteria: they are older than 18 years of age and
had contact with their GP in the past four months for one
of the following reasons: psychological or social prob-
lems, muscle or skeletal pain, fatigue, hyperventilation,
fainting, stomach ache, complaints about functioning of
the heart or head ache. These patients will receive an infor-
mation letter, an informed consent form and the PHQ-22.
Of patients who return the PHQ-22 and give informed
consent, the score on the PHQ-22 will be calculated.
Patients will be considered screen-positive if they answer
affirmatively to the screening questions of the PHQ22 and
list at least 4 symptoms for panic or at least 1 symptom for
general anxiety [46]. For PD, threshold criteria will be
used [49], where as for GAD the sub threshold criteria will
be used to increase sensitivity [50]. Screen-positive
patients will enter the diagnostic phase and will be con-
tacted by telephone to perform a diagnostic interview.
Diagnostic phase
Diagnostic interviews will be conducted by trained
research assistants who will be blind to the randomiza-
tion scheme. The MINI-PLUS International Neuropsychi-
atric Interview is a semi-structured interview that is often
used for DSM-IV classification [51,52]. Telephone admin-
istered psychiatric interviews are found to have a high
concordance with in-person interviews [53]. The inter-
viewers will have the opportunity to consult a psychiatrist,
who is also blind to randomization status, when they are
uncertain of a diagnosis. Patients with a primary diagnosis
of PD and/or GAD and who do not meet any of the exclu-
sion criteria will receive a second information letter, base-
line questionnaires and a second informed consent form.
Patients will be offered the choice of a pen and paper ver-
sion or an internet based version of the questionnaire. If
the patient returns the baseline questionnaires and gives
informed consent, the patient will be included in the
study. Patients in the CSC group will be invited for a con-
sultation with the care manager whereas patients in the
CAU group will be advised to seek contact with their GP
for treatment of their anxiety complaints. GPs in the con-
trol group will not be notified of the diagnosis of partici-
pating patients. Figure 2 shows a flowchart of
participating patients.
Sample size
The aim of the trial is to detect a clinically relevant differ-
ence of 0.5 SD (Cohen's effect size) of CSC versus CAU on
the continuous measure of the Beck Anxiety Inventory
(BAI) [54]. Sample size calculation is based on scores of
281 primary care patients in the multisite Netherlands
Study of Depression and Anxiety (NESDA) [55] with a
diagnosis of PD or GAD in the last six months. The mean
BAI score in this sample was 16.94, with an SD of 10.49
(range 0-58). Hence, the expected difference between CSC
and CAU is 6 points on the BAI. To demonstrate this dif-
ference with alpha = 0.05 and a power of 0.90, 64 cases
per arm are needed ((1.96 + 1.28)2 *10.492 *2)/62). Since
the average class size (n) is estimated to be 5 and the intra-
class correlation coefficient (rho) is expected to be 0.01
[56,57], we apply an inflation factor of 1.04 (inflation fac-
tor = 1 + (n-1) × rho = 1 + 4 * 0.01 = 1.04) [58]. To be able
to analyze 67 completers per arm and with an estimated
25% loss to follow-up, we aim to include 89 patients per
arm.
Intervention
Training
Care managers randomized to the intervention group will
receive three days of training in the nature of anxiety dis-
orders, collaborative care, the guided self-help interven-Page 4 of 12
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Flowchart of participantsigure 2
Flowchart of participants. GP: general practitioner, PCP: primary care practice, PHQ22: Patient Health Questionnaire anx-
iety sub-scale, MINI-interview: MINI-International Neuropsychiatric Interview.
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training sessions will be conducted by a psychologist
(AM), the psychiatrist who developed the guided self help
method [59] and two experienced cognitive behavioral
therapists working at the regional mental health centre
Rivierduinen.
GPs in the intervention group will receive three hours of
training in the recognition of anxiety disorders, motivat-
ing patients for treatment, collaborative care and the med-
ication algorithm. A psychiatrist (AvB), a GP (HvM) and a
psychologist (AM) will provide this training.
Consultant psychiatrists will receive two hours of training
in collaborative care, medication for PD and/or GAD and
giving consultations in primary care. Two psychiatrists
(AvB and CFC) and a psychologist (AM) will provide this
training.
Treatment in the intervention group
1. Collaborative stepped care
In accordance with the collaborative care model, care is
provided by a team of the GP, the care manager, the
patient and a consultant psychiatrist. The collaborative
stepped care intervention is composed of four steps:
1) Guided self-help
2) Cognitive behavioral therapy (CBT)
3) Antidepressants according to a medication algorithm
4) Optimization of medication in primary care or referral
to secondary care
After each step, progress is evaluated with the Beck Anxiety
Inventory (BAI) [60]. The goal of the intervention is
remission, according to the BAI score (See 7. Monitoring
for remission criteria). If a patient does not achieve criteria
for remission after concluding a step, he or she proceeds
with the next step. For example, when a patient does not
achieve criteria for remission concluding the guided self-
help program (step one), he or she is offered CBT treat-
ment (step 2). In contrast, when a patient does achieve
remission after the guided self-help program, he or she
enters a program of relapse prevention.
The care manager coordinates care, delivers guided self-
help and CBT and evaluates each step. The GP prescribes
medication and evaluates progress with the care manager.
The care manager as well as the GP can consult a consult-
ant psychiatrist about treatment decisions. The active
phase of the treatment lasts for at least 12 weeks and has
a maximum of 34 weeks. Patients' adherence to the pro-
gram is enhanced by contracting and active monitoring.
Relapse prevention is provided by the care manager
through monthly follow-up calls, until twelve months
after the beginning of treatment. Figure 3 depicts the treat-
ment algorithm.
2. Contracting
When a patient is included in the study, he or she is
invited for a first meeting with the care manager and GP.
They shortly discuss the patients symptoms and explain
the diagnosis. The patient is actively involved in the treat-
ment plan by contracting. The patient receives a copy of
the treatment plan.
3. Improving adherence
Premature termination of treatment and diminished
adherence to treatment are associated with poorer out-
comes. Therefore, patient adherence is encouraged by psy-
cho-education, goal setting and by frequent follow-up
appointments in which both adherence and progress are
evaluated. Provider adherence to the treatment protocol is
encouraged by instructions from the researchers and
newsletters, by frequent reporting about the care given, by
recording of sessions and by regular supervision. Care
managers attend a supervision group lead by a cognitive
behavioral therapist every three weeks. They also have the
opportunity to discuss problems and exchange experi-
ences through an intranet forum.
Treatment algorithmFigure 3
Treatment algorithm. *Remission is defined as a 50% 
reduction in score on the BAI plus a score of 11 or below. CM = 
care manager, GP = general practitioner, CP = consultant 
psychiatristPage 6 of 12
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Step one in the intervention is a guided self-help method
based on cognitive behavioral principles [61]. This inter-
vention was proven effective in a randomized controlled
trial with patients with PD and/or GAD [29]. In twelve
weeks, the patient works through a self-help manual with
information about anxiety disorders, automatic thoughts,
relaxation techniques and exposure in vivo [62]. Every
chapter contains exercises for the patients to perform. In
five short consultations spread over twelve weeks, the care
manager informs the patient about the content of the
manual, reinforces achievements and motivates the
patient to continue. In addition, the patient is encouraged
to find a "helper", a friend or a relative, who can help him
or her perform exercises and support the patient to adhere
to the program.
5. Cognitive Behavioral Therapy (CBT)
CBT has been proven effective in numerous studies for
both PD and GAD and is recommended as a first line
treatment in international guidelines [63,64]. For this
study, a short duration protocol was developed based on
(inter)national guidelines and available manuals for the
treatment of anxiety disorders with CBT [12,65,66].
A separate treatment protocol for PD and GAD is used,
depending on the primary diagnosis of the patient. The
CBT comprises a course of 6 sessions of 45 minutes pro-
vided by the care manager. All fundamental elements of
CBT are represented in this protocol. For PD the main top-
ics are psycho-education (e.g. the "cycle of panic"), regis-
tration of panic attacks, interoceptive exposure,
recognition and modification of anxiety evoking auto-
matic thoughts and behavioral experiments. The protocol
for GAD focuses on psycho-education, recognition and
modification of anxiety evoking automatic thoughts and
meta-cognitions [67]. Both protocols employ homework
assignments.
6. Medication
GPs are encouraged to adhere to an antidepressant algo-
rithm to optimize the prescription of antidepressants. The
choice of recommended antidepressants was based on
(inter)national guidelines. The algorithm includes time to
titrate to daily dosages (2 weeks), time to respond (par-
tially or remission, 4 weeks) and step-up criteria and
methods (e.g. 'partial response: increase dose', 'no
response: switch medication'). The care manager moni-
tors adherence, adverse effects and response to treatment
with the BAI. The GP and the care manager consult a psy-
chiatrist when necessary. If the patient fulfils criteria for
remission, medication treatment should be continued
until twelve months after the initiation of medication
treatment. If the patient does not respond or adhere to
medication, the GP contacts the psychiatrist to discuss the
options for further treatment. If further treatment in the
primary care setting is not feasible, the patient may be
referred to specialty mental health care.
7. Monitoring
The care manager monitors anxiety symptoms with the
BAI [60]. The goal of the intervention is remission,
defined as a 50 percent reduction in score plus a score of
11 or below (see Secondary outcome measures). At the start
of treatment the care manager administers the BAI and
calculates a "target score" (remission) for each patient.
The care manager then assesses the BAI at the end of step
one and step two. During step three (medication), the care
manager monitors symptoms more frequently: in week
four and eight of medication use. If the patient switches
medication this pattern is repeated.
8. Relapse prevention
If a patient achieves remission after step one, two or three,
relapse prevention is offered by the care manager. The care
manager calls the patient every month, to assess anxiety
symptoms with the BAI. If the BAI score of a remitted
patient increases to a score of 12 or above on two consec-
utive measurements, the care manager consults the psy-
chiatrist about the next step to be taken. The patient can
"step up" to the next step (i.e. step 2: CBT or step 3: med-
ication) or be referred to specialty mental health care.
Relapse prevention lasts until one year after starting treat-
ment.
9. Referral to specialty mental health care
There can be several reasons for referring a patient to spe-
cialty mental health care: diagnostic uncertainty, complex
psychosocial issues, poor response to treatment, patient
preferences or emerging severe psychopathology. Referral
to specialty mental health care is always discussed with
the consultant psychiatrist.
Treatment in the control group
Half of the PCPs function as a control group. These GPs
and care managers receive no training and they provide
their usual care to their patients. There is a Dutch guide-
line available for all GPs about the treatment of anxiety
disorders in primary care [68]. Care as usual comprises
every form of care the GP is used to offer to his patient
(e.g. watchful waiting, prescription of medication, referral
to a mental health care professional or any other form of
care the GP offers to his patient). The actual content of
usual care will be assessed with the Scale for Medical Uti-
lisation of Health Services [69].
Data collection
Measurement will take place at baseline (T0), three (T1),
six (T2), nine (T3) and twelve months (T4) after inclu-
sion. The filled out pen and paper questionnaires will bePage 7 of 12
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The internet-questionnaires will be processed automati-
cally.
Outcome parameters
1. Primary outcome measure
The severity of anxiety symptoms is measured with the
Beck Anxiety Inventory (BAI) [60]. This measure lists 21
symptoms of anxiety like feeling hot, scared or nervous.
Patients are instructed to rate how much each of these
symptoms bothered them in the past week, including
today. Each item can be rated on a 4 point Likert scale,
ranging from 0 (Not at all) to 3 (Severely) yielding a max-
imum total score of 63 points. The instrument has good
psychometric properties [70].
2. Secondary outcome measure
Remission
As there is no standard "remission score" for the BAI, we
calculated this score following the criteria of clinical sig-
nificance of Jacobson & Truax [71]. These authors state
that the best method to define recovery is to calculate the
mean between the mean score of a population with the
disorder and the mean score of a population without the
disorder. We were able to derive these data of patients
with or without PD or GAD from the NESDA study [55],
resulting in a score of 11. Because the BAI score is not a
part of the diagnostic procedure, it is expected that not
every patient will score 11 or higher on the BAI. Therefore,
we added the element of a 50 percent reduction in score
to the definition of remission. In sum, remission is
defined as a score of 11 or below, plus a 50% reduction in
score.
3. Additional outcome measures
Anxiety severity and impairment
Anxiety severity and impairment are measured by the
Overall Anxiety Severity and Impairment Scale (OASIS)
[72]. This scale was developed to measure severity of anx-
iety and impairment caused by anxiety across different
anxiety disorders and showed good reliability and validity
[73]. The scale consists of five questions about frequency
of anxiety, severity of anxiety, avoidance, interference with
tasks and interference of social relationships. The scale
was translated in Dutch according to the forward-back-
ward translation method.
Physical symptoms
Physical symptoms are measured by the Physical Symp-
toms Questionnaire (LKV: Lichamelijke Klachten Vragen-
lijst [74]), which assesses the number and intensity of
functional somatic complaints a patient is experiencing.
The Whitely Index (dimensional version [75,76]) meas-
ures attitudes about diseases (hypochondriasis). As these
symptoms often co-occur with anxiety disorders, it is
interesting to see whether these symptoms also decrease
when treating the anxiety disorder.
Quality of life
Quality of life is a measure that allows comparison in dif-
ferent studies and (mental and physical) disorders. In this
study, quality of life is assessed with the EuroQol (EQ-5D)
[77] and the Short Form-36 (SF-36) [78], both validated
instruments for measuring general health-related quality
of life. The EQ-5D descriptive system consists of five
dimensions (mobility, self-care, usual activities, pain/dis-
comfort, and anxiety/depression), each with three levels
(no problems, some problems, and extreme problems),
thus defining 243 distinct health states. The SF-36 is an
often used measure that assesses eight health concepts
[78].
4. Effect modifiers
Demographic variables
The following demographic variables are measured at
baseline: age, gender, nationality and ethnicity, marital
status, living conditions, education and work status.
Physical illness
Co-morbid physical illness is measured at baseline by
means of a questionnaire developed by Statistics Nether-
lands (the CBS list), which lists 28 chronic conditions
(e.g. diabetes type II and vascular disease). Chronic med-
ical illness is found to be related to more severe symptoms
at baseline, but not to a different treatment response in
the treatment of anxiety disorders [79].
Depressive symptoms
Depressive symptoms are assessed with the depression-
subscale of the Patient Health Questionnaire (PHQ9)
[46,80], a brief and valid instrument which measures each
of the DSM-IV criteria for major depressive disorder. The
total score gives an indication about the severity of depres-
sive symptoms. Depression is related to more severe
symptoms at baseline and after treatment, but not to a dif-
ferent treatment response [81]. Depressive symptoms are
assessed at all measurement points, to see whether depres-
sive symptoms also reside when treating the anxiety disor-
der and to be able to detect a possible difference between
PD and GAD.
Coping
The use of specific coping styles is measured by the
Utrecht Coping List (UCL: Utrechtse Coping Lijst) [82].
This list assesses the frequency of using seven different
coping styles: active coping, palliative reaction, avoidance,
seeking social support, passive coping, expression of emo-
tions and comforting thoughts. Coping styles are found toPage 8 of 12
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debate whether coping styles are sensitive to change fol-
lowing treatment.
Economic evaluation
The aim of this economic evaluation is to assess the cost
effectiveness and to estimate cost utility of CSC compared
to CAU. This will be done by relating the difference in
direct medical costs per patient receiving CSC or CAU to
the difference in terms of reduction in score on the BAI
(cost-effectiveness) and quality adjusted life years (QALY)
gained (cost-utility). This will yield a cost per unit of the
BAI and per QALY estimate. QALY's will be estimated
using the 'Dutch EQ-5D tariff', which is used to calculate
utilities for EQ-5D health states for the cost utility analy-
ses of Dutch health care programs and treatments [84].
The analyses will also be performed including productiv-
ity costs.
Medical costs
For calculating the total direct medical costs, the Trimbos/
iMTA questionnaire for Costs associated with Psychiatric
Illness (TiC-P) [85,86] is used. The Tic-P measures direct
costs of medical treatment such as the number of contacts
with the GP and multiple other care providers (e.g. medi-
cal specialists and paramedics) during the last three
months. Medication use is measured during the last four
weeks. The costs will be estimated in line with the Dutch
guidelines for cost calculations in health care [87].
Reference unit prices of the corresponding health care
services will be applied, and adjusted to the year of the
study according to the consumer price index. Since the
collaborative stepped care model is a new kind of inter-
vention, a unit price per session is currently not available.
To determine a reference price for this intervention a
micro-costing study will be performed in at least three
PCPs delivering the collaborative care intervention. Time
for face-to-face contacts with the patient as well as indirect
time per contact (e.g. mutual consultation contacts
between GP and the care manager or the consultant psy-
chiatrist) will be measured. For reasons of comparison the
costs for a GP contact in the CAU study-arm will be meas-
ured applying a similar micro-costing methodology.
Productivity costs
For collecting data on productivity losses a short form of
the Health and Labour questionnaire (SF-HQL) [88] is
used. The SF-HLQ consists of three modules that measure
productivity losses: absence from work, reduced efficiency
at work and difficulties with job performance [89].
Productivity losses as measured by the SF-HQL are valued
according to the average value added per worker by age
and gender per day and per hour. If respondents indicate
that they have been absent for the entire recall period,
data will be collected from the time when the period of
long-term absence started. This additional information
will be used to value the production losses according to
the "friction cost method" [90]. This method takes into
account the economic circumstances that limit the losses
of productivity to society, which are related to the fact that
a formerly unemployed person may replace a person who
becomes disabled.
Statistical analyses
Intention-to-treat analysis will be performed by multilevel
analysis with time as the first hierarchical level, patients as
the second hierarchical level and care managers with their
PCPs in the third level [91]. Possible confounding charac-
teristics (e.g. age, gender or level of experience) will be
included in the analysis models. Propensity scores will be
used to correct for bias that could be introduced by selec-
tion bias. In this calculation, variables that are not consid-
ered as dependent variables or confounders of interest are
used to predict the chance that a patient is included in
either the CSC or the CAU group, using logistic regression
analysis. This can be considered an appropriate procedure
for cluster randomized trials [43].
Direct and indirect costs of the interventions will be
reported. The results of the cost and QALY analyses will be
presented as mean values with standard errors. Cost-effec-
tiveness and cost-utility analyses will be presented in
incremental cost-effectiveness ratios. The uncertainty will
be assessed using bootstrapping [92] and acceptability
curves will be presented. As principled methods (e.g. mul-
tiple imputation) take into account the special character-
istics of cost data that affect their analysis, a principled
method for dealing with missing data will be applied to
our economic evaluation [93].
Ethical principles
The study protocol has been approved by the Medical Eth-
ical Committee of the VU University Medical Centre at
April 29, 2008 and by the Medical Ethics Committee of
the Leiden University Medical Centre at October 2nd 2008.
Discussion
The presumed poor quality of care in the primary care set-
ting for such prevalent, disabling and costly disorders as
PD and GAD set the basis for this study. The aims of this
study are to improve the quality of care for these patients
with an acceptable increase in costs.
This study is the first in which a stepped care approach is
incorporated in a collaborative care intervention for the
treatment of anxiety disorders in primary care. It is also
the first study, to our knowledge, that evaluates the cost-
effectiveness of such an intervention outside the UnitedPage 9 of 12
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brought together in the protocol of this study.
A strength of this study is its pragmatic design. There is a
minimum of exclusion criteria. Furthermore, care is pro-
vided by health care professionals from the field, unlike in
other studies evaluating collaborative care [36-38]. Con-
sequently, the results of this study may be generalized to
naturalistic health care settings with a comparable pri-
mary health care system and will be easy to implement
into practice.
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